| 1. |
Graus F, Titulaer MJ, Balu R, et al. A clinical approach to the diagnosis of autoimmune encephalitis. Lancet Neurol, 2016, 15(4): 391-404.
|
| 2. |
Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia, 2017, 58(2): 512-521.
|
| 3. |
Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia, 2014, 55(2): 475-482.
|
| 4. |
中国抗癫痫协会. 临床诊疗指南: 癫痫病分册. 北京: 人民卫生出版社, 2015.
|
| 5. |
Beghi E, Carpio A, Forsgren L, et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia, 2010, 51(3): 671-675.
|
| 6. |
Hesdorffer DC, Benn EKT, Cascino GD, et al. Is a first acute symptomatic seizure epilepsy?: mortality and risk for recurrent seizure. Epilepsia, 2009, 50(4): 1102-1108.
|
| 7. |
金丽日, 柳青, 任海涛, 等. 富亮氨酸胶质瘤失活1蛋白抗体阳性边缘系统脑炎一例临床特点. 中华神经科杂志, 2013, 46(7): 461-464.
|
| 8. |
Geis C, Planagumà J, Carreño M, et al. Autoimmune seizures and epilepsy. J Clin Invest, 2019, 129(3): 926-940.
|
| 9. |
Steriade C, Britton J, Dale RC, et al. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: Conceptual definitions. Epilepsia, 2020, 61(7): 1341-1351.
|
| 10. |
Peltola J, Kulmala P, Isojarvi J, et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology, 2000, 55: 46-50.
|
| 11. |
Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain, 2004, 127: 1831-1844.
|
| 12. |
Varadkar S, Bien CG, Kruse CA, et al. Rasmussen’s encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol, 2014, 13: 195-205.
|
| 13. |
Carreño M, Bien CG, Asadi-Pooya AA, et al. Epilepsy surgery in drug-resistant temporal lobe epilepsy associated with neuronal antibodies. Epilepsy Res, 2017, 129: 101-105.
|
| 14. |
de Bruijn M, van Sonderen A, van Coevorden-Hameete MH, et al. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology, 2019, 7(92): e2185-e2196.
|
| 15. |
Liu X, Yan B, Wang R, et al. Seizure outcomes in patients with anti-NMDAR encephalitis: a follow-up study. Epilepsia, 2017, 58: 2104-2111.
|
| 16. |
Steriade C, Gillinder L, Rickett K, et al. Discerning the role of autoimmunity and autoantibodies in epilepsy: a review. JAMA Neurol, 2021, 78(11): 1383-1390.
|
| 17. |
Li Y, Tymchuk S, Barry J, et al. Antibody prevalence in epilepsy before surgery (apes) in drug-resistant focal epilepsy. Epilepsia, 2021, 62(3): 720-728.
|
| 18. |
McGinty RN, Handel A, Moloney T, et al. Clinical features which predict neuronal surface autoantibodies in new-onset focal epilepsy: implications for immunotherapies. J Neurol Neurosurg Psychiatry, 2021, 92(3): 291-294.
|
| 19. |
Thompson J, Bi M, Murchison AG, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain, 2018, 141: 348-356.
|
| 20. |
Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol, 2013, 12: 157-165.
|
| 21. |
Dubey D, Pittock SJ, McKeon A. Antibody prevalence in epilepsy and encephalopathy score: increased specificity and applicability. Epilepsia, 2019, 60(2): 367-369.
|
| 22. |
de Bruijn MAAM, Bastiaansen AEM, Mojzisova H, et al. Antibodies contributing to focal epilepsy signs and symptoms score. Ann Neurol, 2021, 89(4): 698-710.
|
| 23. |
Dubey D, Singh J, Britton JW, et al. Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia, 2017, 58(7): 1181-1189.
|
